Despite the success of chemotherapy regimens in the treatment of acute lymphoblastic leukemia (ALL), certain subsets of patients have a high rate of induction failure and subsequent relapse. One of these subsets of patients carry a translocation between chromosomes 9 and 22, the so called Philadelphia chromosome (Ph þ ). The result of this translocation is the fusion oncogene, BcrAbl, which is uniquely expressed in the leukemia clone, and as such has the potential to initiate antileukemic immune responses against the leukemia blasts. We utilized a murine model of Ph þ ALL to look at the ability of systemic interleukin 12 (IL-12) treatments to initiate antileukemic immune responses, and studied the mechanisms by which it does so. We found that IL-12 was able to eliminate pre-established leukemia, and that this protection was mediated by CD4, CD8, and NK cells in combination. While IL-12 was able to eliminate pre-established leukemia, it did not elicit immunologic memory. Consistent with previous work, vaccination with irradiated leukemia cells transduced with immunomodulator genes was able to establish long-term memory, and, when used with IL-12, was able to eradicate pre-existing disease and induce resistance to subsequent leukemia challenge. These studies demonstrate the feasibility of an immunotherapeutic approach towards the treatment of Ph þ ALL.
A cute lymphoblastic leukemia (ALL) is the most common malignancy in childhood, with a peak incidence between 2 and 5 years of age. 1 Currently, more than 70% of children with ALL are expected to survive as a result of the development and use of combination chemotherapy and treatment strategies tailored to risk group and disease subtypes. 1 3-5% of pediatric patients with ALL have leukemia cells that contain the Philadelphia chromosome translocation (Ph þ ALL), which renders a poor prognosis with a high rate of induction failure and early relapse. 2 As much as 30% of adult ALL may be Ph þ . 3 The Philadelphia chromosome results from a translocation between chromosomes 9 and 22 resulting in the generation of the p190 Bcr-Abl fusion oncogene. The current maximum intensity chemotherapy utilized for high-risk patients such as those with the Philadelphia chromosome cannot be further intensified without causing significant morbidity and mortality.
Hence, future improvements in the treatment of such high-risk groups will arise from new agents developed through the understanding of cellular and molecular mechanisms of disease. One such example is the development of the new agent Imatinib (Gleevec s ), a specific inhibitor of the Bcr-Abl protein. While this targeted small molecule has produced excellent clinical results against the p210 Bcr-Abl gene product in chronic myelogenous leukemia (CML), it has produced mainly short-term responses in patients with the p190 form of BCR/ABL driving Ph þ ALL. 4 An alternative strategy would be to utilize the exclusive expression of oncogenes in leukemia cells to induce specific immune responses against the leukemia cells. This strategy has been studied extensively in other types of malignancies, including melanoma, renal cell carcinomas, and lymphomas. [5] [6] [7] To study the generation of Bcr-Abl-specific immune responses, our laboratory has established a murine model of Philadelphia chromosome positive acute lymphoblastic leukemia (Ph þ ALL) utilizing a cell line, BM185, generated by the transformation of Balb/c bone marrow with the p190 BCR/ABL oncogene. This cell line phenotypically consists of clonal pre-B cells that expand rapidly in vivo and ex vivo. Balb/c mice injected with as few as 1000 cells die within 3-4 weeks of challenge, with heavy leukemia burdens in the blood, spleen, and bone marrow. Irradiated BM185 cells transduced with various immunomodulators are able to initiate antileukemic immune responses, and can prevent the development of leukemia in a portion of mice when given prior to challenge with live wild-type leukemia. [8] [9] [10] Previously, however, we were unable to challenge mice with the minimum lethal dose of leukemia and subsequently treat them using this type of cell vaccine and get any significant survival. 10 Interleukin 12 (IL-12) is a proinflammatory cytokine whose production by dendritic cells and phagocytes stimulates T-cell proliferation and Th1 differentiation, Natural Killer cell proliferation, and NKT cell proliferation through the activation of the Janus Kinase-signal transducer and activator of transcription (JAK-STAT) pathway of signal transduction.
11 IL-12 production is stimulated by products from microorganisms such as bacteria, fungi, dsRNA, bacterial DNA, and CpG oligonucleotides, and is also enhanced by IFN gamma and the CD40L interaction with the CD40 receptor present on antigen presenting cells. 11 Many published reports have demonstrated antileukemic responses initiated by the IL-12 cytokine. [12] [13] [14] In a murine model of acute myelomonocytic leukemia, systemic injections of rmIL-12 as well as leukemia cells expressing mIL-12 afforded protection from otherwise lethal doses of leukemia. 15 Our lab initiated experiments to determine if systemic rmIL-12 injections could be used as an adjuvant to enhance the effects of our leukemia cell vaccine-based strategy and found that rmIL-12 injections alone were able to eliminate disease in mice given lethal doses of leukemia on the same day as the initiation of treatment. 10 To further investigate the use of rmIL-12 in our murine model of Ph þ ALL, we conducted experiments to delineate the mechanism of IL-12 protection operating in our model as well as to establish the strategy most beneficial in generating maximum antileukemic immune responses.
Materials and methods

Mice
Male Balb/c mice, 6-8 weeks old, and a CD1a geneknockout breeding pair in the Balb/c background were purchased from Jackson Laboratories (Bar Harbor, Maine) and maintained in our animal care facility under standard conditions. Balb/c nu/nu mice were purchased from Harlan Bioproducts for Science (Indianapolis, Indiana). Experiments involving mice were all reviewed and approved by the CHLA Institutional Animal Care & Use Committee (IACUC) (Childrens Hospital Los Angeles, Los Angeles, CA).
Cell lines
The BM185 cell lines have been previously described. [8] [9] [10] Briefly, bone marrow from male Balb/c mice was transformed with a retroviral vector containing the human p190 Bcr-Abl oncogene. A clone was selected with a pre-B-cell phenotype and is henceforth referred to as ''BM185''. BM185 cells were modified with retroviral vectors containing either murine CD40L, murine CD80, or murine GM-CSF and highly expressing clones were selected. To generate the cell line containing all three immunomodulators, a highly expressing clone of BM185/ GM-CSF was transduced with a retroviral vector containing murine CD80 which was again selected for a high expressing clone; subsequently, this cell line was transduced a third time with a retroviral vector containing murine CD40L. Thus, the BM185/CD80/CD40L/GM-CSF is a clonal cell line expressing high levels of all three immunomodulators. All BM185 cell lines were maintained in RPMI 1640 medium supplemented with 5% fetal calf serum, 2 mM L-glutamine, 10
À5 M 2-mercaptoethanol, and 100 U/ml penicillin/streptomycin.
Hybridoma cell lines producing antibodies to murine CD4 and murine CD8 (GK1.5 and 53-6.72, respectively) were both obtained from the American Type Culture Collection (ATCC, Rockville MD). GK1.5 was maintained in RPMI 1640 supplemented with 10% fetal calf serum and 100 U/ml penicillin/streptomycin. GK53-6.72 was maintained in IMDM with 1.5 g/l sodium bicarbonate supplemented with 20% fetal calf serum and 100 U/ ml penicillin/streptomycin. All cell lines were incubated at 371C in 5% CO 2 . Monoclonal antibodies were produced by growth of the cells in the appropriate medium, collection of the medium, and isolation of the antibody on a HiTrap Protein G HP affinity column (Amersham Pharmacia Biotech AB, Sweden) with elution using 0.1 M glycine (pH 2.7).
Leukemia challenges and vaccinations
BM185 cell lines were harvested, washed twice in Hanks Balanced Salt Solution (HBSS) and resuspended in HBSS with 50 U/ml of heparin. Leukemia challenges were administered by injecting 1000 live cells in 100 ml volume into the tail vein of mice.
BM185 cells expressing CD80/CD40L/GM-CSF 10 used for vaccinations were washed twice in HBSS, resuspended in HBSS supplemented with 50 U/ml heparin, and irradiated at 3000 cGy in a 137 Cs g irradiator (JL Shepherd & Associates, San Fernando, CA). Vaccinations with 1 Â 10 6 cells in 100 ml volume were delivered by subcutaneous injection in the inguinal region of mice on days þ 1, 5, and 12 after administration of wild-type live leukemia cells.
rmIL-12 administration
Mice were administered 2.5 mg recombinant murine IL-12 (rmIL-12) (R&D Systems) subcutaneously in the inguinal region daily for 5 serial days on days 0-4 and days 14-18 after intravenous challenge with BM185 cells, unless stated otherwise.
In vivo depletions
Balb/c and Nude Balb/c mice were depleted of CD4 þ T cells (hybridoma GK1.5; ATCC) or CD8 þ T cells (hybridoma 53-6.72; ATCC) by intraperitoneal injections of 0.5 mg of the respective monoclonal antibody. Mice were depleted of NK cells by intravenous injection of 50 ml Anti-asialo GM1 (Wako Pure Chemical Industries, Ltd., Osaka, Japan). Mice in the control group were given 0.5 mg polyclonal rat IgG (Rockland, Gilbertsville, PA). Injections were administered on days À6, À3, þ 1, þ 4, and twice weekly thereafter to maintain depletion. One mouse per cohort was killed on day À1, þ 15, þ 30, þ 45, and þ 60 to verify in vivo depletion. A portion of the splenocytes taken from killed mice were analyzed for CD4 þ , CD8 þ , and B220 subpopulations by flow cytometry, and the remaining splenocytes were used in an NK assay against YAC-l targets to test for NK function. Antibodies used to verify depletions by flow cytometry include PE-conjugated Rat anti-mouse CD8a clone 53-6.7, PE-conjugated Rat anti-mouse CD4 clone H129.19, and PE-conjugated Rat anti-mouse CD45R/ B220 clone RA3-6B2 (BD Pharmingen).
NK cell assays
A day prior to harvesting splenocytes, mice were given 100 ml of polyinosinic-polycytidylic acid (Sigma-Aldrich, St. Louis, MO) by intraperitoneal injection. The following day spleens were harvested from mice and single cell suspensions of splenocytes were made and cocultured with 51 Cr-labeled YAC-1 cells (ATCC, Rockville, MD) at 100:1 effector to target ratio for 10-12 hours. YAC-1 lysis was determined by chromium release into the supernatant as measured by a scintillation counter. Percent-specific lysis was calculated with the following equation: Percentspecific lysis ¼ (experimental lysisÀspontaneous lysis)/ (total lysisÀspontaneous lysis) Â 100.
Results
Systemic rmIL-12 treatments eliminate pre-established leukemia
Previously, we determined that rmIL-12 injections were able to eliminate pre-established leukemia in our murine model of Ph þ ALL when given on days 0-5 and 14-18 (with day 0 being the day of inoculation with the wildtype live leukemia challenge). 10 To determine if we were still able to achieve protection with fewer IL-12 treatments, mice were challenged with wild-type leukemia and administered rmIL-12 on two different dose-intensity schedules. Mice given IL-12 injections on days 1-4 and 14-18 (schedule A-nine total doses) had 50-60% survival compared to mice receiving injections on days 1, 5, 12, and 18 (schedule B-four doses) who demonstrated only 25-35% survival (Fig 1a) . Thus, the high frequency of IL-12 treatments in the initial stages of leukemia growth and establishment were crucial in allowing mice to survive the challenge.
To determine whether the concomitant administration of irradiated leukemia cell vaccines affected the efficacy of rmIL-12 given at different dose-intensity schedules, mice were given either the nine dose (schedule A) or the four dose (schedule B) regimen of rmIL-12 plus vaccination with irradiated BM185 cells expressing CD80/C40L/GM-CSF on days þ 1, 5, and 12 after initiation of leukemia cell growth. As we had seen previously, 10 administration of the leukemia cell vaccine did not improve survival when given after leukemia growth had been initiated and had essentially no effect on the efficacy of rmIL-12 (Fig 1b) . The decreased dose-intensity regimen of rmIL-12 (four doses) was still less effective than the higher dose regimen (nine doses), even when given with leukemia cell vaccine.
Protection mediated by rmIL-12 involves the combination of CD4, CD8, and NK cells
To determine the mechanism of protection mediated by rmIL-12 injections, cohorts of mice were depleted of either NK cells, CD4 T cells, or CD8 T cells, and then challenged with wild-type leukemia cells and given rmIL-12 treatments (Table 1 ). Mice depleted of any one of these three cell subsets had protection equivalent to those mice that were depleted with control antibody or not depleted at all (Table 1) . Thus, none of these cell types are absolutely essential for the ability of rmIL-12 to mediate rejection of the pre-established leukemia.
Previous publications have indicated the requirement for NKT cells in IL-12-mediated leukemia protection. 16 To determine if this was the case in our model, we utilized CD1a gene-knockout mice. These mice have been shown to be deficient of NKT cell activity.
17 CD1a geneknockout mice on a Balb/c background were challenged with the BM185 wild-type cell line and provided rmIL-12 treatments on days 1-4 and 14-18 (Table 1) . Mice lacking NKT cell activity had similar survival to Balb/c mice when given IL-12, suggesting the lack of an absolute requirement for NKT cells in our model.
While neither CD4 nor CD8 T cell subsets alone were required for leukemia cell protection mediated by IL-12, we repeated experiments in Balb/c nu/nu mice which lack both CD4 and CD8 T cell subsets to see if protection conferred by rmIL-12 was mediated by both cell types (Fig 2) . Nude mice had decreased survival compared to Balb/c mice indicating that when both CD4 and CD8 subsets were deficient, mice were no longer afforded protection from rmIL-12 to the full extent.
Since the nude mice lacking CD4 and CD8 T lymphocytes did show some, albeit reduced, protection with rmIL-12, we performed additional experiments to determine if NK cells also contributed to the protection mediated by IL-12. Nude mice had their NK cells depleted by treatment with anti-asialo-GM1 antibody and elimination of NK cell activity was confirmed with NK assays. Nude mice depleted of NK cells had less protection from a challenge with BM185 cells by rmIL-12 (Fig 3) . This finding suggests that protection from leukemia by rmIL-12 is mediated by CD4, CD8, and NK cells in combination, but that the different subsets are able to compensate and provide partial protection when one subset is lacking.
Irradiated wild-type leukemia cells do not establish immunologic memory
rmIL-12 treatments alone are able to eradicate existing leukemia cells but are not sufficient to establish longlasting immunity. 10 In order to establish memory and protect mice from subsequent rechallenge with wild-type leukemia cells, irradiated leukemia cells expressing immunomodulators must be given as a vaccine. It has been well documented in the literature that primary leukemia cells are difficult to grow in culture and transduce ex vivo. 18, 19 Therefore, it would be desirable in a clinical setting to use unmodified leukemia cells as a vaccine so that ex vivo manipulations were not needed. It is possible that the immunologic milieu created by the high doses of recombinant IL-12 may allow immune responses to be induced by nonmodified irradiated leukemia cells, obviating the need to genetically modify them.
To evaluate the efficacy of nonmodified irradiated leukemia cells to induce antileukemic immunologic memory when given with rmIL-12, we challenged mice with wild-type leukemia, treated them with rmIL-12 injections and vaccinated them with irradiated leukemia cells made from either nonmodified BM185 cells or from BM185 cells expressing CD80/CD40L/GM-CSF. We observed that irradiated BM185 cells expressing CD80/ CD40L/GM-CSF were able to elicit long-term memory as demonstrated by survival upon secondary challenge with live wild-type BM185 cells (Fig 4) . In contrast, when mice were vaccinated with irradiated wild-type BM185 cells, they did not have greater survival than mice receiving no vaccination when subsequently challenged with live wildtype BM185 cells (Fig 4) . Therefore, the expression of immunomodulators CD80/CD40L/GM-CSF from irradiated BM185 cells is necessary to establish long-lasting immunity, even in the presence of rmIL-12.
Antileukemic immune memory response are mediated by CD4T lymphocytes
A regimen of vaccination of mice carrying a preestablished leukemia burden and injection of rmIL-12 with irradiated BM185 cells expressing CD80, CD40L, and GM-CSF is able to establish long-lasting immunity from subsequent rechallenge with wild-type leukemia. 10 To evaluate the cell subset necessary for the memory response, mice were challenged with BM185 wild-type cells, treated with rmIL-12 and vaccinated with irradiated BM185 cells expressing CD80/CD40L/GM-CSF. Longterm survivors were depleted of either CD4 or CD8 T cells prior to rechallenge with BM185 wild-type cells. Mice depleted of CD4 T cells were no longer protected from rechallenge with the leukemia cells, whereas the cohort of mice that had their CD8 T cells had survival similar to cohorts treated with an irrelevant control antibody and to cohorts that had no depletions performed (Fig 5) . Thus, CD4 T cells are required for the memory response seen in vaccinated mice.
Discussion
Our results demonstrate protection by systemic treatments with recombinant murine IL-12 in mice with preestablished leukemia. The efficacy was dependent on the frequency of treatments following establishment of leukemia by injection of mice with BM185 wild-type cells. This emphasizes the importance of tumor kinetics in our murine model of Ph þ ALL. As few as 1000 BM185 wild- type cells cause death within 3-4 weeks. While various tumor cell vaccines are able to initiate immunologic responses in our murine model, none have been able to prolong survival once leukemia had been pre-established. [8] [9] [10] The success of rmIL-12 injections in our model may relate to the cytokine's ability to expand T-cell subsets, 11 allowing the immune system to keep up with the rapid expansion of tumor cells in vivo. Indirect evidence in support of this is the difficulty we had in depleting T-cell subsets once mice had survived primary challenge with rmIL-12 injections (data not shown). Long-term survivors of mice treated with rmIL-12 plus and minus vaccination were depleted with antibody to determine cell types involved in immunologic memory. Previous experiments in cohorts of mice not treated with rmIL-12 require intraperitoneal injections of antibodies every 3 days for 9 days and then twice weekly injections thereafter. This same regimen in mice who survived primary challenge with rmIL-12 was often times insufficient to fully deplete mice of both CD4 and CD8 T cell subsets (data not shown).
To determine the cell types involved in protection mediated by rmIL-12, we used a combination of depletion studies and challenge in mice deficient in certain cell types. Depletion of either CD4, CD8, or NK cells alone did not affect survival of mice treated with rmIL-12, nor did challenge in mice deficient of NKT cells. When mice were deficient in both CD4 and CD8 cells, however, survival of mice was diminished compared to wild-type mice with intact T and B cells. Survival was further decreased in mice deficient of CD4, CD8, and NK cells. Thus, protection was mediated in part by CD4 T lymphocytes, CD8 T lymphocytes, and NK cells. The ability of IL-12 to activate three different cell types may explain the efficacy seen in our model, where other cytokines alone have failed. The mechanism by which IL-12 activates each of these cell types can be extrapolated from the known functions of this cytokine. We hypothesize that wild-type leukemia cells activate NK and T cells with the presence of IL-12 acting to stimulate rapid expansion and proliferation. The presence of IL-12 also augments cytotoxic activity of CTLs and NK cells by inducing transcription of genes that encode cytotoxic granule-associated molecules such as perforin and granzymes, by upregulating expression of adhesion molecules on antigen presenting cells, and by inducing cytokines such as GM-CSF, TNF, and IFN gamma. Depletion of NK or T-cell subsets alone did not eliminate the protection mediated by IL-12, indicating that the augmentation of cytotoxic CTL activity or NK activity alone was minimal and insufficient to protect mice while together they work in an additive manner as demonstrated by the lack of protection seen in nude mice deficient of NK cells. Combined, the activation of CTLs and NK cells in addition to expansion mediated by IL-12 may account for the elimination of disease in our murine model by CD4, CD8, and NK cells.
The absence of memory responses to recombinant IL-12 alone seen in our model may be explained by the expression of inducible nitric oxide synthase (iNOS) and the production of nitric oxide (NO), which can occur during the proinflammatory reaction initiated by IL-12.
11
NO may induce a temporary immunosuppression that decreases the contribution of antigen-specific immunity to the antileukemia effects of IL-12. Thus, the use of irradiated leukemia cells expressing CD80, CD40L, and GM-CSF function to make up for this lack of memory by inducing long-lasting immunity to the leukemia. Data from previously published experiments have demonstrated that irradiated BM185/CD80 and to a lesser extent BM185/CD40L cells are able to induce memory as seen by protection from subsequent challenge with BM185 wild-type cells, while BM185/GM-CSF irradiated cells were not. [8] [9] [10] Cell lines expressing both CD80 and CD40L (BM185/CD80/CD40L) were not more effective than either alone; however, BM185/CD80/GM-CSF and BM185/CD40L/GM-CSF were more potent than BM185/CD80 and BM185/CD40L cells. The cell line expressing all three immunomodulators initiated the greatest memory response. Thus, it is likely that both CD80 and CD40L are able to initiate memory, while GM-CSF potentiates the response. In the current experiments, this memory response was found to be mediated by CD4 T cells, as demonstrated by the lack of memory response when mice were depleted of CD4 T cells prior to rechallenge of long-term survivors. The initiation of this memory response required the expression of immunomodulators in the tumor cells themselves, as vaccination with irradiated wild-type cells did not afford mice protection from subsequent secondary challenge. Thus, unmodified In combination, IL-12 and our leukemia cell vaccine are effective in eliminating pre-established aggressive Ph þ leukemia and establishing long-lasting immunity from subsequent lethal doses of wild-type leukemia. These results are encouraging as we were previously unable to eliminate pre-established disease in this aggressive model of Ph þ ALL. These studies validate the initiation of a clinical trial evaluating the effects of vaccination in combination with IL-12 on their feasibility, safety, and efficacy when given to patients in remission. We believe this type of adjuvant therapy has the ability to eliminate the presence of minimal residual disease and increase the rate of disease-free survival compared to patients receiving chemotherapy alone.
